289 related articles for article (PubMed ID: 30923130)
1. IL-6 exhibits both
McGregor NE; Murat M; Elango J; Poulton IJ; Walker EC; Crimeen-Irwin B; Ho PWM; Gooi JH; Martin TJ; Sims NA
J Biol Chem; 2019 May; 294(19):7850-7863. PubMed ID: 30923130
[TBL] [Abstract][Full Text] [Related]
2. IL-6 Enhances Osteocyte-Mediated Osteoclastogenesis by Promoting JAK2 and RANKL Activity In Vitro.
Wu Q; Zhou X; Huang D; Ji Y; Kang F
Cell Physiol Biochem; 2017; 41(4):1360-1369. PubMed ID: 28278513
[TBL] [Abstract][Full Text] [Related]
3. The primary function of gp130 signaling in osteoblasts is to maintain bone formation and strength, rather than promote osteoclast formation.
Johnson RW; Brennan HJ; Vrahnas C; Poulton IJ; McGregor NE; Standal T; Walker EC; Koh TT; Nguyen H; Walsh NC; Forwood MR; Martin TJ; Sims NA
J Bone Miner Res; 2014 Jun; 29(6):1492-505. PubMed ID: 24339143
[TBL] [Abstract][Full Text] [Related]
4. Different Soluble Forms of the Interleukin-6 Family Signal Transducer gp130 Fine-tune the Blockade of Interleukin-6 Trans-signaling.
Wolf J; Waetzig GH; Chalaris A; Reinheimer TM; Wege H; Rose-John S; Garbers C
J Biol Chem; 2016 Jul; 291(31):16186-96. PubMed ID: 27226573
[TBL] [Abstract][Full Text] [Related]
5. IL-6 promotes low concentration of RANKL-induced osteoclastic differentiation by mouse BMMs through trans-signaling pathway.
Feng W; Yang P; Liu H; Zhang F; Li M
J Mol Histol; 2022 Jun; 53(3):599-610. PubMed ID: 35661290
[TBL] [Abstract][Full Text] [Related]
6. Zoledronate Enhances Osteocyte-Mediated Osteoclast Differentiation by IL-6/RANKL Axis.
Kim HJ; Kim HJ; Choi Y; Bae MK; Hwang DS; Shin SH; Lee JY
Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30909508
[TBL] [Abstract][Full Text] [Related]
7. Cortical bone maturation in mice requires SOCS3 suppression of gp130/STAT3 signalling in osteocytes.
Walker EC; Truong K; McGregor NE; Poulton IJ; Isojima T; Gooi JH; Martin TJ; Sims NA
Elife; 2020 May; 9():. PubMed ID: 32458800
[TBL] [Abstract][Full Text] [Related]
8. TNF-α Directly Enhances Osteocyte RANKL Expression and Promotes Osteoclast Formation.
Marahleh A; Kitaura H; Ohori F; Kishikawa A; Ogawa S; Shen WR; Qi J; Noguchi T; Nara Y; Mizoguchi I
Front Immunol; 2019; 10():2925. PubMed ID: 31921183
[TBL] [Abstract][Full Text] [Related]
9. Osteocyte-Related Cytokines Regulate Osteoclast Formation and Bone Resorption.
Kitaura H; Marahleh A; Ohori F; Noguchi T; Shen WR; Qi J; Nara Y; Pramusita A; Kinjo R; Mizoguchi I
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708317
[TBL] [Abstract][Full Text] [Related]
10. Osteocytes, not Osteoblasts or Lining Cells, are the Main Source of the RANKL Required for Osteoclast Formation in Remodeling Bone.
Xiong J; Piemontese M; Onal M; Campbell J; Goellner JJ; Dusevich V; Bonewald L; Manolagas SC; O'Brien CA
PLoS One; 2015; 10(9):e0138189. PubMed ID: 26393791
[TBL] [Abstract][Full Text] [Related]
11. WHI-131 Promotes Osteoblast Differentiation and Prevents Osteoclast Formation and Resorption in Mice.
Cheon YH; Kim JY; Baek JM; Ahn SJ; Jun HY; Erkhembaatar M; Kim MS; Lee MS; Oh J
J Bone Miner Res; 2016 Feb; 31(2):403-15. PubMed ID: 26255791
[TBL] [Abstract][Full Text] [Related]
12. Trans-signaling is a dominant mechanism for the pathogenic actions of interleukin-6 in the brain.
Campbell IL; Erta M; Lim SL; Frausto R; May U; Rose-John S; Scheller J; Hidalgo J
J Neurosci; 2014 Feb; 34(7):2503-13. PubMed ID: 24523541
[TBL] [Abstract][Full Text] [Related]
13. Shear stress inhibits IL-17A-mediated induction of osteoclastogenesis via osteocyte pathways.
Liao C; Cheng T; Wang S; Zhang C; Jin L; Yang Y
Bone; 2017 Aug; 101():10-20. PubMed ID: 28414140
[TBL] [Abstract][Full Text] [Related]
14. Secreted frizzled-related protein-1 inhibits RANKL-dependent osteoclast formation.
Häusler KD; Horwood NJ; Chuman Y; Fisher JL; Ellis J; Martin TJ; Rubin JS; Gillespie MT
J Bone Miner Res; 2004 Nov; 19(11):1873-81. PubMed ID: 15476588
[TBL] [Abstract][Full Text] [Related]
15. Glycoprotein130 (Gp130)/interleukin-6 (IL-6) signalling in osteoclasts promotes bone formation in periosteal and trabecular bone.
Johnson RW; McGregor NE; Brennan HJ; Crimeen-Irwin B; Poulton IJ; Martin TJ; Sims NA
Bone; 2015 Dec; 81():343-351. PubMed ID: 26255596
[TBL] [Abstract][Full Text] [Related]
16. Ablation of p38α MAPK Signaling in Osteoblast Lineage Cells Protects Mice From Bone Loss Induced by Estrogen Deficiency.
Thouverey C; Caverzasio J
Endocrinology; 2015 Dec; 156(12):4377-87. PubMed ID: 26441240
[TBL] [Abstract][Full Text] [Related]
17. High mobility group box 1 protein regulates osteoclastogenesis through direct actions on osteocytes and osteoclasts in vitro.
Davis HM; Valdez S; Gomez L; Malicky P; White FA; Subler MA; Windle JJ; Bidwell JP; Bruzzaniti A; Plotkin LI
J Cell Biochem; 2019 Oct; 120(10):16741-16749. PubMed ID: 31106449
[TBL] [Abstract][Full Text] [Related]
18. Vibration enhances osteoclastogenesis by inducing RANKL expression via NF-κB signaling in osteocytes.
Sakamoto M; Fukunaga T; Sasaki K; Seiryu M; Yoshizawa M; Takeshita N; Takano-Yamamoto T
Bone; 2019 Jun; 123():56-66. PubMed ID: 30902792
[TBL] [Abstract][Full Text] [Related]
19. Cross-talk between the interleukin-6 and prostaglandin E(2) signaling systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin/receptor activator of nuclear factor-{kappa}B (RANK) ligand/RANK system.
Liu XH; Kirschenbaum A; Yao S; Levine AC
Endocrinology; 2005 Apr; 146(4):1991-8. PubMed ID: 15618359
[TBL] [Abstract][Full Text] [Related]
20. Pro-inflammatory Cytokines: Cellular and Molecular Drug Targets for Glucocorticoid-induced-osteoporosis via Osteocyte.
Wang T; Yu X; He C
Curr Drug Targets; 2019; 20(1):1-15. PubMed ID: 29618305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
